BackSigilon Therapeutics Overview

Sigilon Therapeutics Current Cash

Sigilon Therapeutics's current cash is $20M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$19.62M
43.20% YoYΔ $-14.92M vs prior year quarter

Peer trimmed avg / median

Loading

Sigilon Therapeutics Current Cash History

Loading

Sigilon Therapeutics vs. peers: Current Cash Comparison

Loading

Sigilon Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sigilon Therapeutics (SGTX) FAQ

As of the most recent data (June 2023), SGTX shows a current cash of $20M. That compares with $35M in the prior-year period — down 43.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SGTX's current cash is now $20M (was $35M) — a 43.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sigilon Therapeutics is outperforming or lagging.

Tracking SGTX's current cash over time shows whether Sigilon Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $20M That compares with $35M in the prior-year period — down 43.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Sigilon Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $20M) with ownership activity and broader fundamentals.

Sigilon Therapeutics's current cash is $20M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.